-+ 0.00%
-+ 0.00%
-+ 0.00%

Actuate Therapeutics' Oral Elraglusib Shows Up to 77% Tumor Growth Inhibition in Preclinical Melanoma Study

PUBT·11/18/2026 13:01:08
Listen to the news
Actuate Therapeutics' Oral Elraglusib Shows Up to 77% Tumor Growth Inhibition in Preclinical Melanoma Study
  • Actuate Therapeutics plans to begin a Phase 1/2 trial of daily oral elraglusib in Q1 2027, initially enrolling patients with refractory metastatic melanoma.
  • Supporting preclinical results presented at ENA 2026 on November 18 showed oral elraglusib alone inhibited melanoma growth, with greater activity at higher exposures.
  • Treatment also shifted the tumor immune environment toward greater antitumor activity.
  • Human safety and drug-exposure data from Phase 1 will guide dose selection for Phase 2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180800PRIMZONEFULLFEED9880036) on November 18, 2026, and is solely responsible for the information contained therein.